Alvero et al. [12] demonstrated that CSCs derived from ovarian tumour samples have a unique CD44+/MyD88+ phenotype, which facilitated resistance to both tumour necrosis factor (TNF) induced apoptosis and cytotoxic therapy. Here, MYD88 is linked to ovarian neoplasm.